|
Patent landscape, scope, and claims: |
Analysis of United States Patent 9,717,796
United States Patent 9,717,796, granted on August 1, 2017, to Eli Lilly and Company, covers a method of treating a neurological or psychiatric disorder using a specific pharmaceutical composition. The patent claims a method for inhibiting the activity of the tau protein kinase 1 (TPK1), also known as the glycine-N-methyltransferase (GNMT) enzyme, within a subject. This inhibition is achieved by administering a specific compound, identified as (S)-3-amino-N-(4-((4-(2-methoxybenzoyl)piperazin-1-yl)methyl)phenyl)butanamide, or a pharmaceutically acceptable salt thereof. The primary therapeutic targets include Alzheimer's disease, Parkinson's disease, and schizophrenia.
What is the Core Invention Claimed in Patent 9,717,796?
The central claim of Patent 9,717,796 is a method of treating a neurological or psychiatric disorder. This method involves administering a specific chemical compound.
- Compound: (S)-3-amino-N-(4-((4-(2-methoxybenzoyl)piperazin-1-yl)methyl)phenyl)butanamide.
- Mechanism of Action: Inhibition of TPK1 (glycine-N-methyltransferase) activity.
- Target Disorders: Alzheimer's disease, Parkinson's disease, schizophrenia.
- Dosage Form: Pharmaceutically acceptable salt of the compound.
The patent asserts that by inhibiting TPK1, the method effectively treats the aforementioned disorders. The specification details the chemical structure of the active compound and provides examples of its synthesis and in vitro efficacy.
What are the Specific Claims within Patent 9,717,796?
Patent 9,717,796 contains multiple claims, each delineating a specific aspect of the invention. The primary claims focus on the method of treatment and the pharmaceutical compositions.
Key Claims:
- Claim 1: A method for treating a neurological or psychiatric disorder in a subject, comprising administering to the subject a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof. Formula I is defined as (S)-3-amino-N-(4-((4-(2-methoxybenzoyl)piperazin-1-yl)methyl)phenyl)butanamide.
- Claim 2: The method of claim 1, wherein the disorder is Alzheimer's disease.
- Claim 3: The method of claim 1, wherein the disorder is Parkinson's disease.
- Claim 4: The method of claim 1, wherein the disorder is schizophrenia.
- Claim 5: A pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- Claim 6: The pharmaceutical composition of claim 5, further comprising one or more additional therapeutic agents.
The patent also includes claims related to specific salt forms of the compound and potential combination therapies. The scope is primarily directed towards the therapeutic application of the specific molecule.
What is the Chemical Identity and Structure of the Active Compound?
The active compound is identified by its chemical name and a specific stereochemical configuration.
- Chemical Name: (S)-3-amino-N-(4-((4-(2-methoxybenzoyl)piperazin-1-yl)methyl)phenyl)butanamide.
- Structure: The structure involves a central phenyl ring substituted with a butanamide group. This butanamide has an amino group at the 3-position and an (S) stereochemistry. The phenyl ring is further substituted with a methylene linker attached to a piperazine ring. This piperazine ring is functionalized with a 2-methoxybenzoyl group.
The patent includes a Markush structure to define a genus of related compounds, but the independent claims are directed to the specific compound named above.
What is the Declared Mechanism of Action for the Patented Compound?
The patent asserts that the compound functions by inhibiting TPK1, which is also identified as GNMT.
- Target Enzyme: TPK1 (Tau Protein Kinase 1), also known as Glycine-N-methyltransferase (GNMT).
- Action: Inhibition of enzyme activity.
- Significance: Inhibition of TPK1 is presented as the means by which the compound exerts its therapeutic effect on neurological and psychiatric disorders. The patent implies that aberrant TPK1 activity is a contributing factor to these conditions.
What are the Specified Therapeutic Indications?
Patent 9,717,796 explicitly lists three primary categories of disorders for which the claimed method of treatment is applicable.
- Alzheimer's Disease: A neurodegenerative disease characterized by progressive cognitive decline and memory loss.
- Parkinson's Disease: A progressive neurodegenerative disorder affecting movement.
- Schizophrenia: A serious mental disorder in which individuals interpret reality abnormally.
The patent does not claim treatment for a broader range of neurological or psychiatric conditions, focusing specifically on these three.
What is the Patent Landscape for TPK1 Inhibitors and Related Therapies?
The patent landscape for TPK1 inhibitors and therapies targeting the pathways associated with Alzheimer's, Parkinson's, and schizophrenia is complex and competitive. Several entities are researching compounds that modulate TPK1 or related tau-targeting mechanisms.
- Key Players: Eli Lilly and Company (holder of 9,717,796), AbbVie, Bristol-Myers Squibb, Merck, and various academic institutions and smaller biotechnology firms.
- Therapeutic Targets: While TPK1 is a focus, other related targets include BACE1, GSK-3β, and various tau aggregation inhibitors.
- Drug Development Stages: The field includes preclinical candidates, compounds in Phase I, II, and III clinical trials, and approved therapies for symptomatic relief, though none are directly TPK1 inhibitors targeting the mechanism described in 9,717,796.
- Patent Activity: There is ongoing patent activity around novel TPK1 inhibitors, new salt forms, formulations, and methods of use for these and related compounds. Generic landscape analysis for compounds structurally similar to the one claimed in 9,717,796 would reveal potential overlap in chemical space.
What are the Implications of Patent 9,717,796 for Pharmaceutical R&D and Investment?
Patent 9,717,796 grants Eli Lilly and Company exclusive rights to a specific method of treating certain neurological and psychiatric disorders using a TPK1 inhibitor.
- R&D Strategy: Companies developing TPK1 inhibitors or alternative therapies for Alzheimer's, Parkinson's, or schizophrenia must conduct thorough freedom-to-operate analyses to avoid infringement. This patent establishes a protected claim for a specific mechanism and compound.
- Investment Outlook: Investment in companies pursuing similar therapeutic approaches needs to account for the existence and scope of this patent. Potential licensees or developers of alternative mechanisms would be unaffected, but direct competitors targeting the same compound or method would face licensing obligations or legal challenges.
- Market Exclusivity: The patent provides market exclusivity for the claimed method of treatment until its expiration, which is typically 20 years from the filing date, subject to potential patent term extensions.
What are the Key Takeaways?
- Core Innovation: Patent 9,717,796 protects a method of treating Alzheimer's disease, Parkinson's disease, and schizophrenia by inhibiting TPK1 (GNMT) with (S)-3-amino-N-(4-((4-(2-methoxybenzoyl)piperazin-1-yl)methyl)phenyl)butanamide.
- Exclusive Rights: Eli Lilly and Company holds exclusive rights for the claimed method of treatment, impacting competitive R&D and investment strategies.
- Competitive Landscape: The neurological and psychiatric disorder therapeutic space is active, with multiple companies pursuing various targets, necessitating careful freedom-to-operate assessments.
- Mechanism of Action: The patent is grounded in the specific inhibition of TPK1 as the therapeutic modality.
Frequently Asked Questions
-
What is the expiration date of Patent 9,717,796?
The patent was granted on August 1, 2017. The term of a U.S. patent is generally 20 years from the filing date, subject to adjustments and extensions. The original expiration would likely be in the early to mid-2030s, depending on the application filing date and any patent term extensions.
-
Does this patent cover the compound itself, or only the method of treatment?
While the patent claims both the method of treatment and pharmaceutical compositions containing the compound, the primary novelty and inventive step are often centered around the method of using this specific compound for the claimed therapeutic indications by inhibiting TPK1. The claims should be reviewed for precise scope.
-
Can generic versions of this treatment be developed after the patent expires?
Yes, after the expiration of the patent's term and any applicable extensions, generic manufacturers can typically develop and market treatments using the compound, provided no other valid patents or regulatory exclusivities are in place.
-
Are there other patents protecting TPK1 inhibitors for neurological disorders?
The patent landscape is extensive. While 9,717,796 specifically claims a method involving one compound, other patents may exist covering different TPK1 inhibitors, alternative salt forms, specific formulations, or different methods of treating neurological disorders with TPK1 modulation.
-
What are the known side effects or adverse events associated with TPK1 inhibition?
The patent specification itself may not extensively detail clinical side effects, as it focuses on patentable novelty. Information on side effects would typically be found in clinical trial data, regulatory filings (e.g., FDA labels), and scientific literature for any compounds that reach advanced development stages.
Citations
[1] Eli Lilly and Company. (2017). Method of treating neurological or psychiatric disorders using a TPK1 inhibitor (U.S. Patent No. 9,717,796). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
